Benchmark lowered the firm’s price target on Humacyte (HUMA) to $10 from $11 and keeps a Buy rating on the shares after updating the firm’s model for some recent financing activity, noting that its new price target is based on a sum-of-the-parts analysis.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HUMA: